Exenatide therapy in insulin-treated type 2 diabetes and obesity

QJM: An International Journal of Medicine

Volumn 103, Issue 9, 2010, Pages 687-694

  Nayak, U A ^a   Govindan, J ^a   Baskar, V ^a   Kalupahana, D ^a   Singh, B M ^a  

^a NEW CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; FRUCTOSAMINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTPATIENT CARE; PRIORITY JOURNAL; THERAPY EFFECT; WEIGHT REDUCTION;

EID: 77955915187     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq112     Document Type: Article

References (22)

1. UK Prospective Diabetes Study (UKPDS). Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patient with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
2. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycaemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-43.
3. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26:3080-6.
4. Stotland NL. Overcoming psychological barriers in insulin therapy. Insulin 2006; 1:38-45.
5. National institute of clinical excellence. Obesity: Guidance on prevention, identification, assessment and management of overweight and obesity in adults and children. Guideline 43. [http://www.nice.org.uk/CG43] (Accessed 6 July 2010).
6. Zhaoping L, Margaret M, Wenli T, Walter M, Arterburn D, Shugarman LR, et al. Meta-Analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142:532-46.
7. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004; 5:51-68.
8. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724-37.
9. National institute of clinical excellence. Type 2 diabetes: Newer agents for blood glucose control in type 2 diabetes. Guideline 87. [http://www.nice.org.uk/CG87] (Accessed 6 July 2010).
10. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows (GWAA Study Group). Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomised trial. Ann Intern Med 2005; 143:559-69.
11. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or sulfonylurea: a multinational, randomized, open-label, two-period crossover noninferiority trial. Clin Ther 2007; 29:2333-48.
12. Nauck M, Frid A, Hermansen K, Shah N, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, Glimepiride, and placebo, all in combination with Metformin, in type 2 diabetes. Diabetes Care 2009; 32: 84-90.
13. Edwards CMB, Winocour PH. ABCD position statement on incretin mimetics and DPP-4 inhibitors - 2009. Pract Diab Int 2009; 26:191-4.
14. Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D. Long-term weight loss from life style intervention benefits blood pressure? Hypertension 2009; 54:756-62.
15. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:3082-9.
16. Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000; 232:515-29.
17. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, et al. Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus. Ann Surg 2003; 238:467-85.
18. Kadera BE, Lum K, Grant J, Pryor AD, Portenier DD, DeMaria EJ. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis 2009; 5:305-9.
19. Zeni T, Kapur S, Lark TR, Magid P. Diabetes Mellitus and insulin resolution after laparoscopic Roux-en-Y gastric bypass (Abstract). Surg Obes Relat Dis 2009; 5:S49.
20. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007; 13:444-50.
21. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes. Endocr Pract 2008; 14:285-92.
22. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009; 31:1511-23.